Target LDL cholesterol levels in high-risk populations in Slovakia: a retrospective study
Authors:
Tibor Porubän 1; Dominik Pella 1; Daniel Pella 2
Authors‘ workplace:
I. kardiologická klinika LF UPJŠ a VÚSCH, a. s., Košice
1; II. kardiologická klinika LF UPJŠ a VÚSCH, a. s., Košice
2
Published in:
AtheroRev 2026; 11(1): 15-22
Category:
Overview
Background: Elevated LDL cholesterol (LDL-C) levels directly affect cardiovascular risk. European recommendations for the preferred method of lowering LDL-C indicate a combination of lifestyle changes and pharmacological treatment, which is the dominant component. Despite the relatively widespread prescription of lipid-lowering drugs, many European patients, including Slovak patients, do not achieve the recommended LDL-C target values. This retrospective analysis examined the actual patterns of lipid-lowering treatment and the level of achievement of LDL-C target values in a large cohort of patients in Slovakia. Methods: This study was conducted as a retrospective analysis of anonymized LDL-C values from 2020–2023 provided by a collaborating laboratory. Overall, The study included patients diagnosed with acute coronary syndrome, stroke, and generally patients with very high cardiovascular risk. Achievement of LDL-C targets was evaluated using the thresholds established in the 2019 European guidelines. Results: A total of 366,077 LDL-C test records from 116,978 patients were analyzed. Among patients with ACS, only 2.2–5.0 % achieved the LDL-C target value < 1.4 mmol/l in individual years. The proportion of patients with extremely high LDL-C ≥ 4.9 mmol/l ranged between 6–7 %. In patients with stroke, 4.0–6.6 % reached the LDL-C target values, while 3.6–6.7 % had LDL-C levels ≥ 4.9 mmol/l. In the group of patients with very high cardiovascular risk overall, only 1.7–3.0 % achieved LDL-C
Keywords:
dyslipidemia – cardiovascular risk – target values – retrospective analysis – LDL cholesterol
Sources
- Lindstrom M, DeCleene N, Dorsey H et al. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990–2021. J Am Coll Cardiol 2022; 80(25): 2372–2425. Dostupné z DOI: <http://dx.doi.org/10.1016/j. jacc.2022.11.001>.
- Burger AL, Pogran E, Muthspiel M et al. New Treatment Targets and Innovative LipidLowering Therapies in VeryHighRisk Patients with Cardiovascular Disease. Biomedicines 2022; 10(5): 970. Dostupné z DOI: <http:// dx.doi.org/10.3390/biomedicines10050970>.
- Shapiro MD, Bhatt DL. “CholesterolYears” for ASCVD Risk Prediction and Treatment. J Am Coll Cardiol 2020; 76(13): 1517–1520. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.08.004>.
- Liu BQ, Yang C, Wei HY et al. Global, regional, and national burden of ischemic heart disease attributable to metabolic risks: a systematic analysis of Global Burden of Disease 2021. J Geriatr Cardiol 2025; 22(3): 361–380. Dostupné z DOI: <http://dx.doi.org/10.26599/1671–5411.2025.03.009>.
- Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ ehab484>.
- [GBD 2021 Risk Factors Collaborators]. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403(10440): 2162–2203. Dostupné z DOI: <http:// dx.doi.org/10.1016/S0140–6736(24)00933–4>. Erratum in: Lancet 2024; 404(10449): 244. Dostupné z DOI: <http://dx.doi.org/10.1016/ S0140–6736(24)01458–2>.
- [World Health Organization]. Cardiovascular diseases (CVDs) – Key facts. WHO 2023. Dostupné z WWW: <https://www.who.int/newsroom/ factsheets/detail/cardiovasculardiseases(cvds)>.
- Timmis A, Vardas P, Townsend N et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022; 43(8): 716 – 799. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab892>. Erratum in: Eur Heart J 2022; 43(8): 799. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehac064>.
- Baigent C, Blackwell L, J Emberson et al. [Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
- Sabatine MS, Wiviott SD, Im K et al. Efficacy and Safety of Further Lowering of LowDensity Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Metaanalysis. JAMA Cardiol 2018; 3(9): 823–828. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2018.2258>.
- Mach F, Koskinas KC, Roeters van Lennep JE et al. 2025 Focused Update of the 2019 ESC/EAS. Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46(42): 4359–4378. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehaf190>. Erratum in: Eur Heart J 2025: ehaf1036. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf1036>.
- Štatistický úrad Slovenskej republiky. Demografická štatistika – Úmrtnosť 2022. ŠÚ SR, Bratislava 2023. Dostupné na WWW: <https://datacube. statistics.sk>.
- Národné centrum zdravotníckych informácií. Zdravotnícka ročenka Slovenskej republiky 2022. NCZI. Bratislava 2023. ISBN 978–80–7508–470–1. Dostupné z WWW: <https://www.nczisk.sk/Aktuality/Pages/ZdravotnickarocenkaSlovenskejrepubliky2022.aspx>.
- Gonçalvesová E, Danková M. Čo vieme o epidemiológii srdcového zlyhávania na Slovensku a vo svete.[What we know about epidemiology of heart failure in Slovakia and globally]. Vnitr Lek 2018; 64(9): 839–846.
- Studenčan M, Hricák V, Kovár F et al. Manažment akútnych koronárnych syndrómov na Slovensku v roku 2015. Aktuálne analýzy registra SLOVAKS. Cardiology Lett 2017; 26(3): 125–137.
- Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESCEORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26(8): 824–835. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487318825350>.
- Tóth Š, Pella D. Ako sme na tom s dosahovaním cieľových hladín LDLcholesterolu na Slovensku u vysokorizikovej populácie: retrospektívna štúdia. AtheroRev 2022; 7(2): 110–115.
- Laššánová M. Fixná kombinácia atorvastatínu s ezetimibom – oveľa viac ako len zníženie LDLC: charakteristiky pacientov a manažment HLP u pacientov so stabilnou KCHS na Slovensku, štúdia DYSIS II. Kompendium medicíny. XXI. kongres Slovenskej kardiologickej spoločnosti: 6.8. október 2016, Bratislava: výber z prednášok. ISSN 1336–4871. Č. 10 (2016), s. 87–91.
- Ray KK, Molemans B, Schoonen WM et al. EUWide CrossSectional Observational Study of LipidModifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2021; 28(11): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaa047>.
- Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehz455>. Erratum in: Eur Heart J 2020; 41(44): 4255. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz826>.
- Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387 – 2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2026 Issue 1
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Hope Awakens with Early Diagnosis of Parkinson's Disease Based on Skin Odor
- Memantine Eases Daily Life for Patients and Caregivers
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
-
All articles in this issue
- Aktualizované odporúčania ESC/EAS 2025: dyslipidémia v centre modernej kardiovaskulárnej prevencie
- The position of combined treatment in the context of updated ESC/EAS recommendations for the management of dyslipidemias
- Bempedoic acid in the updated recommendations for the management of dyslipidemias ESC/EAS 2025
- Target LDL cholesterol levels in high-risk populations in Slovakia: a retrospective study
- Metabolic dysfunction associated steatotic liver disease: from pathogenesis to clinical cardio-metabolic implications
- Current view on lipoprotein(a): diagnosis and treatment
- Atherosclerosis risk and CV risk reduction in GLP1-RA treated patients
- Patients with HIV – management of dyslipidemia, arterial hypertension, and cardiovascular risk: new challenges in the era of effective antiretroviral therapy
- Prevention of anthracycline-induced cardiotoxicity as a new potential indication for statins?
- Artificial intelligence in cardiovascular risk management: from digital medical history to personalized therapy
- The impact of ultra-processed foods on dyslipidemia
- Research on remarkable articles from international literature
- Rok 2025 – rok významných kardiologických studií
- Athero Review
- Journal archive
- Current issue
- About the journal
Most read in this issue
- The position of combined treatment in the context of updated ESC/EAS recommendations for the management of dyslipidemias
- Target LDL cholesterol levels in high-risk populations in Slovakia: a retrospective study
- Metabolic dysfunction associated steatotic liver disease: from pathogenesis to clinical cardio-metabolic implications
- Current view on lipoprotein(a): diagnosis and treatment